An act relating to health insurance coverage for diabetes treatment
H.207 would amend Vermont’s health insurance diabetes coverage law to require insurers to cover equipment, supplies, and outpatient self-management training and education for several categories of diabetes, including insulin-dependent, insulin-using, gestational, and noninsulin-using diabetes. The bill also covers medical nutrition therapy when prescribed by an authorized health care professional. It keeps the existing coverage mandate but removes language that currently allows an insurer to require that the prescription or care be provided by a health care professional under contract with the insurer.
The bill further strengthens the coverage mandate by prohibiting cost-sharing for the required diabetes benefits. Under the proposal, these benefits could not be subject to copayments, coinsurance, deductibles, dollar limits, or other cost-sharing requirements. It applies to health insurance companies, nonprofit hospital and medical service corporations, and health maintenance organizations, but not to specified disease or other limited benefit coverage. The effective date is January 1, 2026, with application to plans issued, renewed, or otherwise offered on or after that date, and no later than January 1, 2027.
H.207 would amend 8 V.S.A. § 4089c, Vermont’s diabetes treatment coverage statute, by expanding consumer protections in health insurance plans. It would remove insurer discretion to limit diabetes-related prescriptions and care to in-network or contracted providers and would bar cost-sharing for the mandated diabetes benefits. The bill would therefore increase the scope and affordability of required diabetes coverage for insured Vermonters and impose additional coverage obligations on regulated health insurers, HMOs, and nonprofit hospital and medical service corporations.
Based on the bill text and the absence of recorded committee testimony or votes, the available context suggests a generally supportive policy direction focused on improving access to diabetes care and reducing out-of-pocket costs. The bill’s purpose statement is straightforward and consumer-protective, indicating an intent to strengthen existing coverage rather than create a new program. No contrary positions are documented in the provided materials.
The main points of potential contention are the elimination of insurer flexibility to require contracted providers and the prohibition on all cost-sharing for the mandated diabetes benefits. Insurers may view these provisions as limiting network management and increasing premium or utilization costs, while patient advocates and people with diabetes would likely support them as necessary to ensure access and affordability. Because no committee transcript or vote record is provided, no specific legislator, stakeholder, or organized opposition is identified in the available context.